Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Smoking Cessation
Interventions: CP-526,555 (varenicline); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 7
States / cities: Los Angeles, California • Farmington, Connecticut • Minneapolis, Minnesota + 4 more

Conditions: Ulcerative Colitis
Interventions: OPC-6535 Tablets (drug); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 28
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 25 more

Conditions: Arthritis, Rheumatoid
Interventions: SKI-O-703 capsule, Placebo capsule; Drug
Lead sponsor: Oscotec Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cardiovascular
Interventions: AZD1705, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Glendale, California • Jacksonville, Florida • Winter Park, Florida + 2 more

Conditions: Cardiomyopathy Due to Anthracyclines
Interventions: Allo-MSCs, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: Stanford, California • Gainesville, Florida • Miami, Florida + 4 more

Conditions: Dry Eye
Interventions: Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, Reproxalap Ophthalmic Solution (0.25%) QID to BID, Vehicle Ophthalmic Solution QID to BID; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions: standard therapy, placebo, activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 7
States / cities: Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 4 more

Conditions: COVID-19
Interventions: MP0420, Placebo, Remdesivir; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 73
States / cities: Tucson, Arizona • Chula Vista, California • Fresno, California + 52 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Epratuzumab; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 791 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 49
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hemet, California + 44 more

Conditions: Diabetic Macular Edema
Interventions: Aflibercept, Faricimab, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 50
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 44 more

Conditions: Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression, Post-Natal Depression, Peripartum Depression
Interventions: LPCN 1154A, Placebo; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 16
States / cities: Tucson, Arizona • Canoga Park, California • Walnut Creek, California + 13 more

Conditions: Healthy Volunteers, Hepatitis C Virus
Interventions: RO5024048; Drug
Lead sponsor: Pharmasset; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more

Conditions: Schizophrenia
Interventions: Talnetant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 20
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 17 more

Conditions: Hyperphagia in Prader-Willi Syndrome
Interventions: FE 992097, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 3
States / cities: Gainesville, Florida • Mineola, New York • Nashville, Tennessee

Conditions: Management of Chronic Pain
Interventions: Hydromorphone Hydrochloride, Programmable Implantable pump; Drug · Device
Lead sponsor: Piramal Critical Care, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: LNP023, Eculizumab, Ravulizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Orange, California • Augusta, Georgia + 2 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Bremelanotide, Placebo; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 87
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more

Conditions: FSGS
Interventions: APL2, Placebo; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Marfan Syndrome
Interventions: Exercise Intervention Group, Control Group; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis, Knee
Interventions: Celecoxib, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 27 more

Conditions: Mid-facial Volume Deficit Related to Aging
Interventions: Juvéderm® VOLUMA XC; Device
Lead sponsor: Allergan; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: NBI-1065845, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Little Rock, Arkansas • Garden Grove, California • Orange, California + 15 more

Conditions: Chronic Total Occlusion of Coronary Artery
Interventions: NovaCross; Device
Lead sponsor: Nitiloop Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Little Rock, Arkansas • Naperville, Illinois • New York, New York + 1 more

Conditions: Influenza
Interventions: Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose, Flufirvitide-3, 0.4 mg single dose, Placebo; Drug · Other
Lead sponsor: Autoimmune Technologies, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Stem Cell Injection in Cancer Survivors

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

Brexanolone Lifting Outcomes Of Moms

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

Marfan Syndrome Moderate Exercise Trial II

Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects